Latest developments, partnerships and scientific breakthroughs
Together with the Basel Biozentrum and the Institute of Medical Microbiology in Zurich, leadXpro solved the structure of the bacterial transporter LptDE to provide structural basis for the design of novel antibiotics.
leadXpro CEO Michael Hennig showcases examples of successful structure based drug discovery for challenging membrane targets
leadXpro supports Creoptix at the launch event for the new waveRAPID kinetics analyzer
On December 2, 2020, leadXpro proudly celebrates its fifth anniversary and looks back on many successful projects with challenging membrane targets.
Axxam, leadXpro and MercachemSyncom Form a Strategic Alliance for Structure-based Drug Discovery Services that will allow them to offer world-class integrated structure-guided drug discovery services for membrane protein targets.
leadXpro AG announces its involvement in a multiparty research collaboration by delivering SARS-CoV-2 M-glycoprotein, a promising therapeutic target against Covid-19.
One month after the groundbreaking ceremony of Park Innovaare’s new Innovation Campus, leadXpro is the first company to sign a tenancy agreement.
Lundbeck partners with leadXpro to discover drugs for membrane protein targets by high-resolution X-ray and cryo-Electron Microscopy
Astex Pharmaceuticals partners with leadXpro to facilitate structure-based drug discovery for membrane protein targets by cryo-Electron Microscopy
By licensing cryosparc software and upgrading of its in-house computing capacity, leadXpro enhances its ability for high resolution structure determination of membrane protein drug targets by single particle cryo-Electron Microscopy (cryo-EM)